The Solvent Problem: Peptide Manufacturing Is Scaling Into a Regulatory Squeeze
GLP-1 demand pushed peptide synthesis to metric-ton scale. At the same moment the EU restricted DMF and added DMAc and NEP to Annex XVII. The chemistry that makes peptides runs on solvents Europe is phasing out.
Solid-phase peptide synthesis runs on polar aprotic solvents, principally DMF and NMP, and green-chemistry reviews put solvent at roughly 80–90% of the process waste stream. The EU has been restricting exactly that solvent class: DMF entered Annex XVII of REACH as entry 76, restricted since 12 December 2023 above 0.3%, and DMAc and NEP followed as entries 80 and 81, published in the Official Journal in June 2025 with compliance dates in 2026. This is happening at the precise moment GLP-1 demand has pushed peptide API production from kilograms toward metric tons and triggered a consolidation wave — most recently CordenPharma's closing of its AmbioPharm acquisition on 3 August 2026. Capacity is being built in a solvent regime that is being withdrawn.
Condor Research supplies characterised reference materials for laboratory research use only. This article is process chemistry and industry analysis. Nothing here is a therapeutic claim or a recommendation to use any compound in humans.
Why the chemistry is solvent-hungry
Solid-phase peptide synthesis is elegant and wasteful in equal measure, and the two are the same feature.
The chain is built on a resin bead. A protected amino acid is coupled to the growing chain, the protecting group is removed, the bead is washed, and the cycle repeats for every residue. A thirty-residue peptide is thirty cycles, each with couplings, deprotections and multiple wash steps.
The washing is the whole point of the method. Anchoring the peptide to a solid support is what allows excess reagents and by-products to be rinsed away rather than separated chromatographically at every step — that is why SPPS displaced solution-phase synthesis. It is also where the solvent goes. Reviews of green chemistry in this field put solvent at roughly 80–90% of the waste, dominated by DMF and NMP.
Those solvents are not incidental. They swell polystyrene resin properly, which is what gives reagents access to the growing chain, and they dissolve protected amino acids. The chemistry works in them and works considerably worse in most alternatives.
The regulatory squeeze
DMF was added to Annex XVII of REACH as entry 76. Since 12 December 2023 it may not be placed on the market or used industrially or professionally, on its own or in mixtures above 0.3%, unless specified conditions are met — with occupational exposure limits of 6 mg/m³ by inhalation and 1.1 mg/kg/day dermal.
N,N-dimethylacetamide (DMAc) and 1-ethylpyrrolidin-2-one (NEP) followed as entries 80 and 81, published in the Official Journal in June 2025, with compliance dates falling in 2026. The restriction dossier came from the Netherlands, and the grounds are occupational: this solvent class carries reproductive toxicity concerns and absorbs readily through skin.
The substitution problem has proved harder than expected, and the literature is consistent about why. No single green solvent replaces DMF across the board. The best current results come from binary mixtures — DMSO or N-butylpyrrolidone with a co-solvent. A parallel line of work attacks the problem from the other end, pairing solvent recycling with swellable macroporous polystyrene resins to cut how much solvent a given synthesis consumes in the first place.
For a manufacturer this is a constraint with a hard timeline. A process validated in DMF is a process written into a regulatory filing. Changing the solvent means re-validating, re-characterising the impurity profile, and amending submissions. Doing that during a demand peak is not a comfortable position, and it is a genuine reason why European and US capacity decisions are being made now rather than later.
The scale that makes it urgent
For most of the history of peptide therapeutics, an API campaign meant kilograms. The GLP-1 class ended that. Industry analyses now describe production requirements measured in multi-kilogram quantities and in some cases metric tons, with capital expenditure for a single production facility that can exceed $500 million.
Multiply an 80–90% solvent waste fraction by ton-scale production and the waste figure stops being a laboratory inconvenience and becomes a permitting, handling and disposal problem at industrial scale — in the jurisdiction that is simultaneously restricting the solvent.
What the consolidation is buying
We covered the Samsung Biologics tender offer for PolyPeptide separately; CordenPharma’s acquisition of AmbioPharm, which closed on 3 August 2026, is the same thesis with a different emphasis, and the detail is instructive.
The South Carolina site (formerly AmbioPharm, North Augusta) adds downstream capability: enhanced purification and expanded lyophilisation, with upstream investment planned. The Shanghai site adds upstream capacity. CordenPharma frames the result as fully US-based peptide API supply through the pairing of South Carolina with its existing Colorado site, while Frankfurt covers Europe and Shanghai covers Asia — a combined organisation of roughly 3,500 people across three continents.
The recurring phrases are “geographic flexibility” and “supply chain resilience”. What is being bought is not only tonnage but the ability to offer a customer the same peptide from more than one jurisdiction. Where trade policy, biosecurity legislation, regional sourcing preferences and — as above — divergent solvent regulation are all in motion, multi-jurisdiction capability is itself a product feature.
The upstream/downstream split deserves attention too. Upstream builds the chain. Downstream is purification and isolation — chromatography, lyophilisation — the steps that determine what the impurity profile actually looks like in the final material. FDA’s July 2026 revisions to its generic peptide guidances — and the EMA synthetic peptide guideline on the European side — put impurity control, higher order structure and biological activity at the centre of peptide quality. Investment in downstream capability is investment in exactly the properties regulators have just raised the bar on.
Why this reaches the research market
Three consequences, none speculative.
Precursor competition is shared. Protected amino acids, coupling reagents and resins feed one supply chain regardless of what the final peptide is for. When ton-scale commercial programmes consume that chain, availability and pricing for everything else move with it.
The quality floor rises. A facility built to supply a regulated commercial programme runs validated analytical methods, defined impurity specifications, stability programmes and change control. Manufacturers who can operate at that standard become distinguishable from those who cannot, and the documentation gap becomes visible rather than theoretical.
Provenance becomes answerable. For a research buyer the useful questions are the ordinary industrial ones. Where was the material actually synthesised. Is the batch documented. Does the certificate of analysis correspond to the specific lot supplied, or to a representative batch tested at some earlier point. Which analytical methods were used, and are the chromatograms available. These have always been answerable in principle; as the manufacturing base professionalises they become answerable in practice — which is most of what separates one European supplier from another.
The larger point
Peptide chemistry spent decades as a specialist discipline. Within about three years it has become an industrial sector with capital expenditure at the scale of semiconductor fabs, a solvent problem serious enough to have its own line in European chemicals law, and a consolidation wave rearranging who can make what and where.
The molecules have not changed. The constraint has moved from the chemistry to the infrastructure around it — and in Europe, specifically, to the question of what you are still permitted to dissolve it in.
Related reading
- Solid-phase peptide synthesis is solvent-intensive; green chemistry reviews put solvent at roughly 80–90% of the process waste stream, dominated by DMF and NMP.
- DMF entered REACH Annex XVII as entry 76, restricted since 12 December 2023 above 0.3%, with occupational exposure limits of 6 mg/m³ by inhalation and 1.1 mg/kg/day dermal.
- DMAc and NEP followed as entries 80 and 81, published in the Official Journal in June 2025 with compliance dates in 2026.
- No single green solvent replaces DMF; the best current results use binary mixtures such as DMSO or N-butylpyrrolidone with a co-solvent.
- CordenPharma closed its acquisition of AmbioPharm on 3 August 2026, adding downstream purification and lyophilisation in South Carolina and upstream capacity in Shanghai.
Why does peptide synthesis use so much solvent?
Each coupling and deprotection cycle is followed by wash steps, and that washing is precisely what makes solid-phase synthesis work.
Is DMF banned in Europe?
It is restricted, not banned. Since 12 December 2023 it may not be placed on the market or used industrially above 0.3% unless specified conditions, including exposure limits, are met.
What replaces DMF in peptide synthesis?
No single solvent does. Binary mixtures of DMSO or N-butylpyrrolidone with a co-solvent give the best results reported so far.
Why does manufacturing consolidation matter to a research buyer?
Precursors and capacity are shared across the sector, and facilities built for regulated programmes run validated methods and documented batches, which raises the documentation standard across the market.